Relay Therapeutics, Inc. (RLAY)

NGM – Цена в реальном времени. Валюта: USD

12.93

+0.08 (0.62%)

При закрытии: May 12, 2026, 4:00 PM EDT

12.94

+0.01 (0.04%)

После закрытия: May 12, 2026, 7:08 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Relay Therapeutics, Inc. (RLAY)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Relay Therapeutics, Inc. (RLAY)

Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Lags Revenue Estimates

Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates

Buy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash Runways

Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026

Relay Therapeutics, Inc. (RLAY) Discusses Zovegalisib Triplet Data and First-Line Breast Cancer Strategy Transcript

Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer

Relay Therapeutics (RLAY) Surges 16.4%: Is This an Indication of Further Gains?

Видео

No Data

Пресс-релизы

Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates

Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer

Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026

Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones

Search stocks

Relay Therapeutics, Inc. (RLAY)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Relay Therapeutics, Inc. (RLAY)

Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Lags Revenue Estimates

Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates

Buy These 3 Clinical-Stage Biotechs Under $30 With Solid Cash Runways

Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026

Relay Therapeutics, Inc. (RLAY) Discusses Zovegalisib Triplet Data and First-Line Breast Cancer Strategy Transcript

Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer

Relay Therapeutics (RLAY) Surges 16.4%: Is This an Indication of Further Gains?

Видео

No Data

Пресс-релизы

Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates

Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer

Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026

Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones